Financhill
Sell
46

MDGL Quote, Financials, Valuation and Earnings

Last price:
$291.14
Seasonality move :
-7.12%
Day range:
$288.00 - $294.40
52-week range:
$200.63 - $377.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.98x
P/B ratio:
9.09x
Volume:
293.3K
Avg. volume:
372.6K
1-year change:
33.98%
Market cap:
$6.5B
Revenue:
$180.1M
EPS (TTM):
-$18.05

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MDGL
Madrigal Pharmaceuticals
$114.2M -$3.79 985.75% -48.55% $421.93
ALNY
Alnylam Pharmaceuticals
$581.2M -$0.37 -5.16% -5.09% $320.62
BBIO
BridgeBio Pharma
$57.7M -$1.00 4530.37% -18.53% $58.78
CYTK
Cytokinetics
$2.6M -$1.36 706.05% -8.01% $73.45
UTHR
United Therapeutics
$729.3M $6.54 12.23% 25.78% $388.18
VKTX
Viking Therapeutics
-- -$0.31 -- -120.34% $90.26
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MDGL
Madrigal Pharmaceuticals
$290.96 $421.93 $6.5B -- $0.00 0% 19.98x
ALNY
Alnylam Pharmaceuticals
$285.31 $320.62 $37.2B -- $0.00 0% 15.62x
BBIO
BridgeBio Pharma
$33.84 $58.78 $6.4B -- $0.00 0% 50.18x
CYTK
Cytokinetics
$31.00 $73.45 $3.7B -- $0.00 0% 186.93x
UTHR
United Therapeutics
$305.35 $388.18 $13.8B 12.18x $0.00 0% 4.92x
VKTX
Viking Therapeutics
$27.40 $90.26 $3.1B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MDGL
Madrigal Pharmaceuticals
14.24% 1.767 1.61% 5.41x
ALNY
Alnylam Pharmaceuticals
89.88% 1.597 2.91% 2.84x
BBIO
BridgeBio Pharma
925.32% 1.067 28.12% 4.31x
CYTK
Cytokinetics
168.01% 0.673 13.74% 5.89x
UTHR
United Therapeutics
2.85% 1.506 1.44% 5.05x
VKTX
Viking Therapeutics
-- -0.956 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MDGL
Madrigal Pharmaceuticals
$132.7M -$79.3M -43.17% -49.57% -50.96% -$88.9M
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
BBIO
BridgeBio Pharma
$114M -$103.8M -145.93% -- -109.29% -$200.8M
CYTK
Cytokinetics
-$98.3M -$155.6M -121.06% -- -8766.94% -$137.3M
UTHR
United Therapeutics
$701.9M $382.8M 18.69% 19.92% 54.08% $386.3M
VKTX
Viking Therapeutics
-- -$55.5M -- -- -- -$31.2M

Madrigal Pharmaceuticals vs. Competitors

  • Which has Higher Returns MDGL or ALNY?

    Alnylam Pharmaceuticals has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -9.67%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
  • What do Analysts Say About MDGL or ALNY?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.62 which suggests that it could grow by 12.38%. Given that Madrigal Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Madrigal Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    ALNY
    Alnylam Pharmaceuticals
    12 8 1
  • Is MDGL or ALNY More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.104%.

  • Which is a Better Dividend Stock MDGL or ALNY?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or ALNY?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus 15.62x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    19.98x -- $137.3M -$73.2M
    ALNY
    Alnylam Pharmaceuticals
    15.62x -- $594.2M -$57.5M
  • Which has Higher Returns MDGL or BBIO?

    BridgeBio Pharma has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -143.55%. Madrigal Pharmaceuticals's return on equity of -49.57% beat BridgeBio Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    BBIO
    BridgeBio Pharma
    97.74% -$0.88 $209.5M
  • What do Analysts Say About MDGL or BBIO?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 73.69%. Given that BridgeBio Pharma has higher upside potential than Madrigal Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    BBIO
    BridgeBio Pharma
    10 3 0
  • Is MDGL or BBIO More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

  • Which is a Better Dividend Stock MDGL or BBIO?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or BBIO?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than BridgeBio Pharma quarterly revenues of $116.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus 50.18x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    19.98x -- $137.3M -$73.2M
    BBIO
    BridgeBio Pharma
    50.18x -- $116.6M -$167.4M
  • Which has Higher Returns MDGL or CYTK?

    Cytokinetics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -10220.14%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Cytokinetics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    CYTK
    Cytokinetics
    -6223.05% -$1.36 $391.7M
  • What do Analysts Say About MDGL or CYTK?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand Cytokinetics has an analysts' consensus of $73.45 which suggests that it could grow by 136.94%. Given that Cytokinetics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Cytokinetics is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    CYTK
    Cytokinetics
    9 3 0
  • Is MDGL or CYTK More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.173%.

  • Which is a Better Dividend Stock MDGL or CYTK?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or CYTK?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Cytokinetics quarterly revenues of $1.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than Cytokinetics's net income of -$161.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus 186.93x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    19.98x -- $137.3M -$73.2M
    CYTK
    Cytokinetics
    186.93x -- $1.6M -$161.4M
  • Which has Higher Returns MDGL or UTHR?

    United Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of 40.56%. Madrigal Pharmaceuticals's return on equity of -49.57% beat United Therapeutics's return on equity of 19.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    UTHR
    United Therapeutics
    88.36% $6.63 $7B
  • What do Analysts Say About MDGL or UTHR?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand United Therapeutics has an analysts' consensus of $388.18 which suggests that it could grow by 27.13%. Given that Madrigal Pharmaceuticals has higher upside potential than United Therapeutics, analysts believe Madrigal Pharmaceuticals is more attractive than United Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    UTHR
    United Therapeutics
    6 6 0
  • Is MDGL or UTHR More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.76%.

  • Which is a Better Dividend Stock MDGL or UTHR?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or UTHR?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than United Therapeutics's net income of $322.2M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus 4.92x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    19.98x -- $137.3M -$73.2M
    UTHR
    United Therapeutics
    4.92x 12.18x $794.4M $322.2M
  • Which has Higher Returns MDGL or VKTX?

    Viking Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -49.57% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    VKTX
    Viking Therapeutics
    -- -$0.41 --
  • What do Analysts Say About MDGL or VKTX?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 45.01%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 229.43%. Given that Viking Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    VKTX
    Viking Therapeutics
    10 2 0
  • Is MDGL or VKTX More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

  • Which is a Better Dividend Stock MDGL or VKTX?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or VKTX?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Viking Therapeutics quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 19.98x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    19.98x -- $137.3M -$73.2M
    VKTX
    Viking Therapeutics
    -- -- -- -$45.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Unity Software a Buy Now?
Is Unity Software a Buy Now?

Unity Software (NYSE:U) is the company behind the popular Unity…

Will Uber Stock 5X?
Will Uber Stock 5X?

Uber (NYSE:UBER) has generated extremely strong returns for its investors…

How High Will Bloom Energy Stock Go?
How High Will Bloom Energy Stock Go?

Bloom Energy (NYSE:BE) has seen its shares surge by more…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
81
SMLR alert for May 17

Semler Scientific [SMLR] is up 28.56% over the past day.

Sell
25
GLOB alert for May 17

Globant SA [GLOB] is down 23.54% over the past day.

Buy
94
HIMS alert for May 17

Hims & Hers Health [HIMS] is up 10.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock